Fig 1: Alpha-2-HS-glycoprotein (AHSG) and extracellular matrix protein 1 (ECM1) as non-invasive biomarkers for non-small-cell lung cancer (NSCLC). A, The expression level of AHSG and ECM1 detected by Western blotting in NSCLC and healthy individuals. B, The concentration of exosomal AHSG in NSCLC patients and healthy donors. C, The concentration of exosomal AHSG in healthy donors (n = 46), NSCLC patients (n = 122), early stage of NSCLC (n = 31). **P < 0.01, ****P < 0.0001. D, The concentration of exosomal ECM1 in NSCLC patients and healthy donors. E, The concentration of exosomal ECM1 in healthy donors (n = 46), NSCLC patients (n = 109), early stage of NSCLC (n = 28). *P < 0.05, ***P < 0.001
Fig 2: Diagnostic value of the combination of exosomal alpha-2-HS-glycoprotein (AHSG), extracellular matrix protein 1 (ECM1), and serum carcinoembryonic antigen (CEA) for non-small cell lung cancer (NSCLC). A,B, Combination of AHSG and CEA to diagnose NSCLC. Receiver operating characteristic (ROC) curves for distinguishing NSCLC patients from healthy donors (A) and early stage NSCLC patients from healthy donors (B). C,D, Combination of ECM1 and CEA to diagnose NSCLC. ROC curves for distinguishing NSCLC patients from healthy donors (C) and early stage NSCLC patients from healthy donors (D). E,F, Combination of AHSG, ECM1, and CEA to diagnose NSCLC. ROC curves for distinguishing NSCLC patients from healthy donors (E) and early stage NSCLC patients from healthy donors (F)
Fig 3: Diagnostic value of exosomal alpha-2-HS-glycoprotein (AHSG) and extracellular matrix protein 1 (ECM1) for non-small cell lung cancer (NSCLC). A,B, Diagnostic value of exosomal AHSG protein. Receiver operating characteristic (ROC) curves for distinguishing NSCLC patients from healthy donors (A) and early stage NSCLC patients from healthy donors (B). C,D, Diagnostic value of exosomal ECM1 protein. ROC curves for distinguishing NSCLC patients from healthy donors (C) and early stage NSCLC patients from healthy donors (D). E,F, Combination of AHSG and ECM1 to discriminate all NSCLC patients. ROC curves for distinguishing NSCLC patients from healthy donors (E) and early stage NSCLC patients from healthy donors (F)
Supplier Page from Proteintech Group Inc for Human Fetuin-A ELISA Kit